Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease

EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments

EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease

EP: 3.Navigating Different Subtypes of Dry Eye Disease

EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes

EP: 5.Updating Formularies: Considerations for Dry Eye Disease

EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease

EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease

EP: 8.Resource Allocation in the Treatment of Dry Eye Disease

EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease

EP: 10.Annual Health Care Costs of Managing Dry Eye Disease

Now Viewing

EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease

EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease

EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease

EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease

This is a video synopsis/summary of a Stakeholder Summit involving:

Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.

Haumschild asks about promising emerging dry eye disease (DED) therapies targeting symptoms and causes. Kabiri cites the recent approval of perfluorohexyloctane, taken 4 times daily, as an effective, safe, accessible treatment specifically addressing the predominant evaporative DED component.

Parekh notes the recent first-in-class evaporative DED treatment approval has generated great enthusiasm after decades of unmet need in this area, joining other emerging options like a new medication for a DED-exacerbating mite, a topical steroid specifically for intermittent DED flares, and pipeline immunomodulators with alternate anti-inflammatory mechanisms. He notes DED’s rising prominence is attracting investments into therapeutic innovation. Kabiri adds that the approved evaporative DED medication has a simple educational message around mechanism. This avoids intimidation barriers that can impede provider adoption and patient compliance relative to emerging therapies.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.